Industry News
Biotechnology Industry News

Roche’s investigational KRAS…
Roche’s investigational KRAS G12C inhibitor has beaten Amgen’s Lumakras and Bristol Myers Squibb’s Krazati in a phase 3 trial, furthering its ambitions to establish divarasib as a new standard of care.
Merck & Co. has nixed the…
Merck & Co. has nixed the phase 2 study of a potential Alzheimer’s disease medicine after the drug underwhelmed in an interim analysis, marking another blow for the pharma’s struggling partner Neuphoria Therapeutics.
Insilico Medicine has signed a…
Insilico Medicine has signed a deal worth up to $600 million with Japanese Big Pharma Takeda to collaborate on discovery of assets across Takeda’s therapeutic areas of interest.
Ipsen is on a roll this week,…
Ipsen is on a roll this week, scooping up its second biotech in three days in order to firm up its pipeline with promising clinical-stage candidates.
QuantumCell has licensed AlzeCure…
QuantumCell has licensed AlzeCure Pharma’s Alzheimer’s disease platform and lead asset for $12 million upfront, bagging a potentially symptom-relieving drug candidate that is on the cusp of phase 2.
Coming on the heels of a $130…
Coming on the heels of a $130 million fundraising round just four months ago, bone-focused Angitia Biopharmaceuticals has pivoted away from its lead asset to structure its pipeline around two earlier-stage drug candidates.
Vijay Kumar, the acting head of…
Vijay Kumar, the acting head of the FDA office that oversees new gene therapies, is stepping down from his role after a year in the job.
Abivax has recovered from a dent…
Abivax has recovered from a dent in its share price after unveiling fresh safety data that appeared to ease investors’ concerns with its ulcerative colitis prospect.
A sharp reduction in layoffs…
A sharp reduction in layoffs continued in the second quarter, extending a trend that started last fall.
Vistagen’s social anxiety…
Vistagen’s social anxiety disorder drug candidate has flunked another phase 3 trial. But, with a post hoc subpopulation analysis linking fasedienol to a nominally statistically significant improvement, the biotech plans to talk to the FDA
U.S.-based Boulevard Bio is paying…
U.S.-based Boulevard Bio is paying $20 million upfront to China’s Metis TechBio for the global rights to a trispecific T-cell engager for autoimmune diseases.
Just two and a half months after…
Just two and a half months after buzzing out of stealth with $300 million and five autoimmune programs from Bristol Myers Squibb, busy Beeline Medicines has flown an extra $126.3 million back to its hive.
After scrapping development on its…
After scrapping development on its diabetic macular edema treatment avoralstat last month, BioCryst has announced it is shuttering all internal discovery programs to focus on external innovation and partnerships.
A phase 2b trial of Evommune’s…
A phase 2b trial of Evommune’s EVO756 has missed its primary endpoint, wiping out a would-be rival to Novartis for the chronic spontaneous urticaria market.
As Neuphoria continues to navigate…
As Neuphoria continues to navigate the fallout of its failed social anxiety program, the biotech is mulling an offer from another potential buyer.
AstraZeneca has shared the data…
AstraZeneca has shared the data behind previously disclosed phase 3 rare disease wins, fleshing out the case for a Strensiq successor tipped to generate blockbuster sales. The company has yet to share data from a
Ipsen is paying $450 million…
Ipsen is paying $450 million upfront to buy U.S.-based Kartos Therapeutics for a phase 3-stage blood cancer drug designed to improve Jakafi treatment.
Alopexx has resuscitated its plans…
Alopexx has resuscitated its plans for a public listing as the biotech seeks urgently needed funds to advance a pipeline that includes an infectious disease antibody that was once the focus of a $375 million
Amid a flurry of traditional IPOs…
Amid a flurry of traditional IPOs this spring, Talawar Therapeutics is taking a different path to the public markets via a merger with a special purpose acquisition company.
Epicrispr Biotechnologies has used…
Epicrispr Biotechnologies has used its gene silencing tech to boost muscle mass in three patients with facioscapulohumeral muscular dystrophy, a clinical first for the debilitating disease with no approved treatments.

